BioCon-900 is a B-mode pulsed-echo ultrasound device. The BioCon-900 projects ultrasonic energy through the lower of a patient to obtain images of the bladder to calculate the urine volume non-invasively. BioCon-900 is intended to be used by a qualified medical professional to non-invasively measure the urine in the bladder. Contraindications for the BioCon-900 are fetal use and use on pregnant patients.

Device Description

CUBEScan™ BioCon-900 (bladder volume measurement system) is a safe and easy, non-invasive system to measure the bladder volume. CUBEScan™ BioCon-900 is a B-mode instrument, hand-held, wireless and battery-operated. A 3D-mechnical sector transducer provides cross-sectional images of the bladder from up to 12 scan planes and bladder volume is calculated based upon those images and displays 12 scan planes on a screen. Furthermore, a live image of the bladder during Pre-Scan makes it easier to detect the bladder before scanning. Measurements are transmitted to a personal computer running CubePro software via a wireless connection. CubePro allows the user to print measurements, archive data and so on.

AI/ML Overview

The provided document is limited to the 510(k) Summary for the CUBEScan™ BioCon-900 (Bladder Volume Measurement System). While it discusses safety and some performance testing, it does not contain a detailed study proving the device meets specific acceptance criteria in the way typically found in clinical validation studies for AI/algorithm performance.

The document primarily focuses on demonstrating substantial equivalence to a predicate device (CUBEScan™ BioCon-700) and compliance with various regulatory standards for medical devices (biocompatibility, electrical safety, acoustic output, software validation).

Therefore, I can only extract limited information relevant to your request, primarily regarding the "Volume Measuring Testing." The other requested items (ground truth, expert consensus, MRMC studies, training set details) are not present in this 510(k) Summary.

Here's an analysis based on the available text:

1. Table of Acceptance Criteria and Reported Device Performance

The document mentions "Volume Measuring Testing" to demonstrate accuracy but does not explicitly state numerical acceptance criteria (e.g., specific accuracy thresholds) or detailed quantitative performance results (e.g., mean absolute error, agreement with reference). It only states that "the accuracy has been demonstrated."

Acceptance Criteria	Reported Device Performance
Not explicitly stated in the provided document	"The accuracy has been demonstrated by designated volume to the volume from CUBEScan™ BioCon-900."

2. Sample Size Used for the Test Set and Data Provenance

Sample Size for Test Set: Not specified. The document only mentions "a tissue-equivalent bladder phantom with a balloon which has a designated volume is used." It doesn't indicate how many different designated volumes were tested or how many measurements were taken for each.
Data Provenance: The test was conducted using a "tissue-equivalent bladder phantom," which means it was an in vitro (laboratory-based) study, not involving human subjects. Therefore, it's neither retrospective nor prospective in a clinical sense, and country of origin for human data is not applicable.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

Number of Experts: Not applicable. The ground truth ("designated volume of the balloon") was established by the physical properties of the phantom, not by human experts.
Qualifications of Experts: Not applicable.

4. Adjudication Method for the Test Set

Adjudication Method: Not applicable. The ground truth was a "designated volume" of a phantom, not subject to expert interpretation or adjudication.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and the Effect Size of How Much Human Readers Improve with AI vs. Without AI Assistance

MRMC Study: No, an MRMC study was not done. This 510(k) summary describes a standalone device (BioCon-900) which is an ultrasound device to measure bladder volume. It is not an AI/algorithm that assists human readers/clinicians, but rather an instrument for measurement. The concept of "human readers improving with AI assistance" does not apply to the testing described.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

Yes, a standalone performance test was done for the device's ability to measure volume from a phantom. The "Volume Measuring Testing" describes the device (CUBEScan™ BioCon-900) directly measuring the volume of a bladder phantom and comparing it to the "designated volume." This is a standalone performance test for the device itself.

7. The Type of Ground Truth Used

Ground Truth Type: "Designated volume" of a balloon within a tissue-equivalent bladder phantom. This is an engineered physical truth.

8. The Sample Size for the Training Set

Sample Size for Training Set: Not specified in this document. The CUBEScan™ BioCon-900 is described as a "B-mode pulsed-echo ultrasound device" with a "3D-mechanical sector transducer." While it uses images to calculate volume, the document does not indicate that it is a machine learning or AI-driven algorithm that requires a "training set" in the conventional sense. The volume calculation is likely based on established ultrasound principles and internal algorithms that may have been developed and refined, but the concept of a separate "training set" as in deep learning is not mentioned or implied.

9. How the Ground Truth for the Training Set Was Established

How Ground Truth for Training Set Was Established: Not applicable, as detailed training set information is not provided nor explicitly relevant to the device as described.

Summary of Limitations as per the provided document:

The provided document is an FDA 510(k) summary primarily focused on demonstrating substantial equivalence and regulatory compliance (safety, EMC, software validation) for a medical device. It offers very limited detail on the specific performance study for bladder volume measurement accuracy, particularly regarding numerical acceptance criteria, detailed results, human subject data, or AI/algorithm-specific validation metrics like those typically requested. The "Volume Measuring Testing" only mentions the type of test (phantom-based comparison to designated volume) without quantifiable outcomes.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other.

June 22, 2017

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

Mcube Technology Co., Ltd. % Mr. Dave Yungvirt CEO Third Party Review Group, LLC The Old Station House 24 Lackawanna Place MILLBURN NJ 07041

Re: K171591

Trade/Device Name: CUBEScan" BioCon-900 (Bladder Volume Measurement System) Regulation Number: 21 CFR 892.1560 Regulation Name: Ultrasonic pulsed echo imaging system Regulatory Class: II Product Code: IYO, ITX Dated: May 28, 2017 Received: June 1, 2017

Dear Mr. Yungvirt:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours.

For

Robert Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health

Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indication for Use

From Approved: OMB No. 0910-0120

Expiration Date: January 31, 2017

See PRA Statement below

510(k) Number (if known)

K171591

Device Name

CUBEScan™ BioCon-900 (Bladder Volume Measurement System)

Indications for use (Describe)

Type of Use (Select one or both, as applicable)

2 Prescription Use (Part 21 CFR 801 Subpart D)

ロ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARETE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

FORM FDA 3881 (8/14)

Page 4 - 1

PSC Publishing Services (301) 443 6740 EF

{3}------------------------------------------------

Diagnostic Ultrasound Indications for Use Form

System:	CUBEScan™ BioCon-900Bladder Volume Measurement System
Transducer:	BioCon-900
	Intended use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:
Clinical Application		Mode of Operation
General(Track 1 Only)	Specific(Tracks 1 & 3)	B	M	PWD	CWD	ColorDoppler	Combined(Specify)	Other* (Specify)
Ophthalmic	Ophthalmic
	Fetal
	Abdominal	N
	Intra-operative (Specify)
	Intra-operative (Neuro)
	Laparoscopic
	Pediatric
FetalImaging& Other	Small Organ (Specify)
	Neonatal Cephalic
	Adult Cephalic
	Trans-rectal
	Trans-vaginal
	Trans-urethreal
	Trans-esoph. (non-Card.)
	Musculo-skeletal(Conventional)
	Musculo-skeletal(Superficial)
	Intravascular
	Other (specify)	P
Cardiac	Cardiac Adult
	Cardiac Pediatric
	Intravascular (Cardiac)
	Trans-esoph. (Cardiac)
	Intra-cardiac
	Other (specify)
PeripheralVessel	Peripheral vessel
	Other

N = new indication; P = previously cleared by FDA in K111021; E = added under this appendix

Examples of other modes of operation may include: A-mode, Amplitude Doppler, 3-D Imaging, Harmonic Imaging, Tissue Motion Doppler, and Color Velocity Imaging

Prescription devices (Part 21 CFR 801.109)

{4}------------------------------------------------

510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with requirements of 21 CFR 807.92.

1) SUBMITTER

Submitter:	Mcube Technology Co., Ltd.
	#803, 123 Bonghwasan-ro,
	Jungnang-gu, Seoul, Korea
Contact Person:	Seung-Tai Kim
	Director
	Phone: +82-(0)2-3421-7780
	Fax: +82-(0)2-3421-7076
	E-mail: mcube@mcubetech.co.kr
Date Prepared:	Feb 15, 2016

2) DEVICE

Trade Name(s):	CUBEScan™ BioCon-900
Common Name:	Bladder Volume Measurement System
Classification:	II
Classification Name(s):	Ultrasonic Pulsed Echo Imaging System	Diagnostic Ultrasound Transducer
Regulation Number:	21 CFR 892.1560	21 CFR 892.1570
Product Code:	IYO	ITX
Classification Panel:	Radiology

3) PREDICATE DEVICE

Predicate Devices:	Mcube Technology Co., Ltd.CUBEScanTM BioCon-700	K111021

4) DEVICE DESCRIPTION

{5}------------------------------------------------

5) INTENDED FOR USE/INDICATIONS FOR USE

BioCon-900 projects ultrasonic energy through the lower abdomen of a patient to obtain images of bladder to calculate the urine volume non-invasively.

6) COMPARISION OF CUBEscan™ BioCon-900 WITH THE PREDICATE DEVICES

The CUBEScan™ BioCon-900 is substantially equivalent to the currently marketed BioCon-700.

The subject and the predicate devices are based on the following same technological elements:

· Intended use: Projection of ultrasonic energy into the abdomen of patients.
Patient population and anatomical site
Measurement of bladder volume
· Accuracy of measurement
Mode of operation
· Transducer type, sector angle, number of element and number of scan planes
· Acoustic output intensity
Displays, portable, button controls, attached printer and PC software for data management
Standards of safety, EMC, biocompatibility

The following technological differences exist between the CUBEScan™ BioCon-900 and predicate devices.

Transducer resonant frequency
Patient contact material
Transducer diameter
· Charger
· Data Transmission tools(Touch screen operation and accessories)
Input of information
PC program version

{6}------------------------------------------------

7) Summary of Non-Clinical Testing Performed

The following performance data were provided in support of the substantial equivalence

Biocompatibility Testing

The biocompatibility test for CUBEScan™ BioCon-900 was conducted in accordance with ISO-10993 as recognized by FDA. The following tests performed:

Cytotoxicity Test (MEM Elution Test)
Maximization Sensation
Intracutaneous Reactivity

Electrical Safety and Electromagnetic Compatibility (EMC)

Electrical safety and EMC testing were conducted on the CUBEScan™ BioCon-900. The CUBEScan™ BioCon-900 complied with AAMI/ANSI ES 6060-1, IEC6060-1-2 for safety and EMC including battery, Ir communication, barcode and wireless charging.

Acoustic Output Testing

The acoustic output test for was CUBEScant™ BioCon-900 conducted in accordance with IEC60601-2-37.

Software Validation

Software Validation testing for CUBEScan™ BioCon-900 was conducted and documentation was provided as recommended "Guidance for the Content of Premarket Submissions for Software in Medical Devices".

Volume Measuring Testing

In order to demonstrate the accuracy of CUBEScan™ BioCon-900, a tissue-equivalent bladder phantom with a balloon which has a designated volume is used. The accuracy has been demonstrated by designated volume to the volume from CUBEScan™ BioCon-900.

Wireless Telecommunication & Charging

The CUBEScan 114 BioCon-900 is intended for use in an environment in which radiated RF disturbances are controlled. In order to demonstrate the safety of RF communications, Wireless Telecommunication Testing was conducted in accordance with 47 CFR FCC - Telecommunications, Chapter I - Federal Communications Commission, Subchapter A - General Part 15 - Radiofrequency Devices Subpart C section 15.207/15.209 and RF Exposure

8) Conclusions

In accordance with the Federal Food, Drug and Cosmetic Act, 21 CFR Part 807 and based on the information provided in this premarket notification. Mcube Technology Co., Ltd. concludes that the CUBEScan™ BioCon-900 is safe and effective and substantially equivalent to predicative devices as described herein.

END of 510(k) Summary

Regulation Number and Section

§ 892.1560 Ultrasonic pulsed echo imaging system.

(a)
Identification. An ultrasonic pulsed echo imaging system is a device intended to project a pulsed sound beam into body tissue to determine the depth or location of the tissue interfaces and to measure the duration of an acoustic pulse from the transmitter to the tissue interface and back to the receiver. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II (special controls). A biopsy needle guide kit intended for use with an ultrasonic pulsed echo imaging system only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.